Generex
Generex: a Year in Review; Setting the Stage
Generex Biotechnology Corp - WORCESTER, Mass., Jan. 6, 2010 (GLOBE NEWSWIRE) -- With over 40 years experience in the rollercoaster ride of drug development and commercialization, I have been fortunate to have been one of the founders and leaders of a number of multi-billion dollar ventures, including theThe collapse of the financial markets in 2008 left the biotechnology world in disarray with sources of capital all but disappearing overnight. This placed many small companies completely reliant on capital financing on the verge of bankruptcy and Generex was no exception. However, through the coordination of efforts of management and a team of new advisors to the company, Generex was able to retire onerous debt and raise traditional capital through a series of common stock offerings at progressively higher prices throughout 2009. Today, Generex has a significant amount of capital to deliver exceptional results and while most people focus on Generex Oral-lyn(TM), the company's buccall insulin spray product (and for good reason as it recently received approval for the use under the USFDA's Treatment Investigational New Drug program), what is often overlooked are two other very promising drug programs with vast market potential.
Generex acquired Antigen Express
In 2003, Generex acquired Antigen Express, Inc., a fledgling biotech company with a number of novel early-stage opportunities. In 2009 we began to see a path to success as the science we acquired has begun to move through the clinical trial process for two potential blockbuster immunotherapeutic vaccine technology programs. First, and furthest along, is its immunotherapeutic synthetic vaccine technologies for cancers (breast, cervical, and prostate). Positive Phase II results for its breast cancer vaccine in 2009 have enabled the company to make preparations for a Phase III study which we hope to commence some time in calendar 2010. According to the National Cancer Institute, over 250,000 women were diagnosed with some form of breast cancer in 2009, and it is the second leading cause of cancer death among women. While this represents a substantial market opportunity for Generex, more importantly, the potential benefit for the millions of women throughout the world prone to breast cancer is staggering and after all, the true goal of every scientist in biotechnology, along with the business opportunity, is to better the life of people suffering from illness. I am pleased to be a part of this important effort at Generex.About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.Home | Advantages and Disadvantages of Leasing | Generex | Site-Map
